Date: 2018-09-21

Type of information: Nomination

Compound: member of the board

Company: InflaRx (Germany)

Therapeutic area: Inflammatory diseases

Type agreement: nomination

Action mechanism:



  • • On September 21, 2018, InflaRx announced that Jens Holstein has been appointed as a new board member of InflaRx, serving as Non-Executive Director. Mr. Holstein has extensive management experience in the biotechnology and healthcare industry and currently serves as CFO of Morphosys. He joined MorphoSys in 2011 from Fresenius, a global healthcare company, where he served as Regional CFO for the Europe/Middle East region of Fresenius Kabi AG, and as Managing Director of Fresenius Kabi Deutschland. Over his nearly 16 years at Fresenius, Mr. Holstein held a variety of financial and general management positions, including Regional CFO of Fresenius Kabi Asia Pacific, Managing Director of Fresenius ProServe GmbH and Chief Financial Officer and Labor Director of the company's subsidiary, Wittgensteiner Kliniken AG. Prior to joining Fresenius, Mr. Holstein spent several years in the consulting industry in Frankfurt and London. He holds a Diploma in Business Administration from the University of Muenster.

Financial terms:

Latest news:

Is general: Yes